Hisamitsu Pharmaceutical Co., Inc.

Equities

4530

JP3784600003

Pharmaceuticals

Market Closed - Japan Exchange 02:00:00 2024-04-19 am EDT 5-day change 1st Jan Change
3,719 JPY -0.51% Intraday chart for Hisamitsu Pharmaceutical Co., Inc. -4.86% -13.73%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Hisamitsu Pharmaceutical Attributable Profit Up 19% in Fiscal 2024 MT
Hisamitsu Pharmaceutical Lifts Fiscal-Year Targets as Nine-Month Profit, Net Sales Rise MT
Hisamitsu Pharmaceutical Co., Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending February 29, 2024 CI
Hisamitsu Pharmaceutical Co., Inc. Announces Dividend for the Second Quarter and Provides Dividend Guidance for the Full Year Ending February 29, 2024 CI
Tranche Update on Hisamitsu Pharmaceutical Co., Inc.'s Equity Buyback Plan announced on July 13, 2023. CI
Hisamitsu Pharmaceutical Co., Inc.'s Equity Buyback announced on July 13, 2023, has closed with 2,000,000 shares, representing 2.58% for ¥9,792.58 million. CI
Tranche Update on Hisamitsu Pharmaceutical Co., Inc.'s Equity Buyback Plan announced on July 13, 2023. CI
Hisamitsu Pharmaceutical’s Attributable Profit up 29.4% in Fiscal Q2 on Improved Net Sales MT
Hisamitsu Pharmaceutical Co., Inc. Reports Earnings Results for the Half Year Ended August 31, 2023 CI
Tranche Update on Hisamitsu Pharmaceutical Co., Inc.'s Equity Buyback Plan announced on July 13, 2023. CI
Hisamitsu Pharmaceutical Attributable Profit More Than Doubles in Fiscal Q1; Shares Climb 11% MT
Hisamitsu Pharmaceutical Co., Inc. announces an Equity Buyback for 2,000,000 shares, for ¥10,000 million. CI
Hisamitsu Pharmaceutical Co., Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending February 29, 2024 CI
Hisamitsu Pharmaceutical Co., Inc. Provides Dividend Guidance for the Second Quarter of Fiscal 2024 and Full Year Ending February 29, 2024 CI
Hisamitsu Pharmaceutical Co., Inc. authorizes a Buyback Plan. CI
Hisamitsu Pharmaceutical Affirms Final Dividend on Higher FY23 Profit, Revenue MT
Hisamitsu Pharmaceutical Co., Inc. Announces Dividend for the Year 2023, Effective May 26, 2023 CI
Hisamitsu Pharmaceutical Co., Inc. Provides Dividend Guidance for the Second Quarter of Fiscal 2024 and Full Year Ending February 29, 2024 CI
Hisamitsu Pharmaceutical Co., Inc. Announces Special Dividend for the Fiscal Year 2023 CI
Hisamitsu Pharmaceutical Co., Inc. Provides Consolidated Earnings Guidance for the Year Ending February 29, 2024 CI
Tranche Update on Hisamitsu Pharmaceutical Co., Inc.'s Equity Buyback Plan announced on October 12, 2022. CI
Hisamitsu Pharmaceutical Co., Inc.'s Equity Buyback announced on October 12, 2022, has closed with 2,000,000 shares, representing 2.51% for ¥7,693.05 million. CI
Hisamitsu Pharmaceutical Co., Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending February 28, 2023 CI
Hisamitsu Pharmaceutical Co., Inc. Provides Special Dividend Guidance for the Fiscal Year 2023 CI
Hisamitsu Pharmaceutical Co., Inc. Provides Year End Dividend Guidance for the Fiscal Year Ending February 28, 2023 CI
Chart Hisamitsu Pharmaceutical Co., Inc.
More charts
Hisamitsu Pharmaceutical Co Inc is a Japan-based company mainly engaged in the pharmaceutical business. The Company is engaged in the manufacture, sale and supply of pharmaceuticals and related products, and the operation of over-the-counter drug (OTC) business. It is also engaged in the manufacture and sale of drugs in the United States, Brazil, Vietnam, and Indonesia, the development work in Europe, the drug marketing and sales in China and Hong Kong. It is also engaged in the urban cable television broadcasting business, Internet connection service business, non-life insurance agency business, advertising agency business and the purchase, manufacture and sale of packing materials.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
3,719 JPY
Average target price
3,950 JPY
Spread / Average Target
+6.21%
Consensus
  1. Stock Market
  2. Equities
  3. 4530 Stock
  4. News Hisamitsu Pharmaceutical Co., Inc.
  5. Hisamitsu Pharmaceutical : Net Profit Slips 63% on Lower Revenues in Fiscal Nine Months; Shares Fall 5%